Samsung Bioepis said Thursday that the company has won “Company of the Year, Asia-Pacific” and “Regulatory Achievement of the Year” awards at the Global Generics & Biosimilars (GGB) Awards 2023.

The GGB Awards is an annual event organized by Citeline, an international publishing company, to recognize notable achievements in the generics and biosimilars industries. Citeline held this year’s event in Barcelona, Spain, on Wednesday.

Samsung Bioepis won the GGB awards for “Company of the Year, Asia-Pacific” category in 2022 and “Biosimilar Initiative of the Year” in 2020. 

The Korean company has been recognized for its best practices and ongoing endeavors to expand treatment options for patients, including those with rare diseases, through biosimilars. In August 2022, the company became the first to receive the U.S. Food and Drug Administration’s approvals for high-concentration and low-concentration adalimumab biosimilar.

Samsung Bioepis has seven biosimilar products approved in Europe and five in the U.S., becoming one of the most expansive and rapidly growing global biopharmaceutical companies since its establishment in 2012.